Home » Newsletters » BioWorld Science

BioWorld Science

July 9, 2009

View Archived Issues

Longer vaccination interval with recombinant malaria vaccine leads to higher immunogenicity

Losartan a possible therapy for AGTR1-overexpressing breast cancer

Prasugrel reduces several types of myocardial infarction in TRITON-TIMI 38 trial

Phenylbutyrate a potential treatment for Alzheimer's disease

Merrimack initiates dosing in phase I/II clinical study of MM-111 in cancer

FDA approves Hyperion's SPA for phase III clinical trial of HPN-100 in adults with UCD

NovaBiotics receives clearance to initiate first-in-man clinical trials of Novexatin

Kuros initiates treatment in phase IIb clinical trial of KUR-211 in diabetic foot ulcers

DermaGen completes patient enrollment in phase I/IIa trial of antimicrobial peptide DPK-060

Bayer submits NDA to FDA for oral contraceptive estradiol valerate/dienogest

Japanese MHLW approves Novartis' Rasilez for high blood pressure

Pluristem begins enrollment for phase I clinical trial of PLX-PAD in critical limb ischemia

ARYx Therapeutics reports results from EmbraceAC phase II/III clinical trial of tecarfarin

Avanir completes enrollment in open-label extension of phase III STAR trial of Zenvia

Ikaria obtains worldwide exclusive license to BioLineRx's BL-1040 for AMI

Peplin completes enrollment in phase III trials of PEP-005 for actinic keratoses

Daiichi Sankyo launches new formulations of antibacterial agent Cravit in Japan

Cell Therapeutics to meet with EMEA in September 2009 to discuss MAA for Opaxio

Shire files treatment protocol with FDA for velaglucerase alfa for Gaucher disease

Univ. California, Clear Vascular patent peptides for the treatment of vascular plaques

Novel cannabinoid CB2 receptor ligands patented by Ipsen Pharma

Hameln rds describes novel ACAT inhibitors for the treatment of lipoprotein disorders

GlaxoSmithKline describes dual histamine H1 and H3 receptor antagonists

Novel inhibitor may allow physiological understanding of fatty acid elongase 6

Wyeth's Enbrel approved in Japan for juvenile idiopathic arthritis indication

Thallion suspends enrollment for phase II trial of TLN-232 due to dispute with licensor

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...